Structure–Activity Relationships and Quantitative Structure–Activity Relationships for Breast Cancer Resistance Protein (ABCG2)
- 650 Downloads
Breast cancer resistance protein (ABCG2), the newest ABC transporter, was discovered independently by three groups in the late 1990s. ABCG2 is widely distributed in the body with expression in the brain, intestine, and liver, among others. ABCG2 plays an important role by effluxing drugs at the blood–brain, blood–testis, and maternal–fetal barriers and in the efflux of xenobiotics at the small intestine and kidney proximal tubule brush border and liver canalicular membranes. ABCG2 transports a wide variety of substrates including HMG-CoA reductase inhibitors, antibiotics, and many anticancer agents and is one contributor to multidrug resistance in cancer cells. Quantitative structure–activity relationship (QSAR) models and structure–activity relationships (SARs) are often employed to predict ABCG2 substrates and inhibitors prior to in vitro and in vivo studies. QSAR models correlate in vivo biological activity to physicochemical properties of compounds while SARs attempt to explain chemical moieties or structural features that contribute to or are detrimental to the biological activity. Most ABCG2 datasets available for in silico modeling are comprised of congeneric series of compounds; the results from one series usually cannot be applied to another series of compounds. This review will focus on in silico models in the literature used for the prediction of ABCG2 substrates and inhibitors.
Key wordsABC transporter ABCG2 breast cancer resistance protein quantitative structure–activity relationships structure–activity relationships
Support was provided by the Susan G. Komen Foundation BCTR0601385 and from Pfizer Inc.
- 4.Robey R, Polgar O, Deeken J, To KK, Bates SE. Breast cancer resistance protein. In: You G, Morris ME, editors. Drug transporters: molecular characterization and role in drug disposition. Hoboken: Wiley; 2007. p. 319–58.Google Scholar
- 12.Minderman H, Brooks T, O’Loughlin KL, Ojima I, Bernacki RJ, Baer MR. Multidrug resistance (MDR) modulation by the taxane derivatives IDN-5109 and tRA 96023: effects on P-glycoprotein (Pgp)-, multidrug resistance protein (MRP-1)-, and breast cancer resistance protein (BCRP)-mediated drug transport. Proc Am Assoc Cancer Res. 2002;43:950.Google Scholar
- 30.Allen JD, van Loevezijn A, Lakhai JM, van der Valk M, van Tellingen O, Reid G, et al. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther. 2002;1:417–25.PubMedGoogle Scholar
- 32.Saito H, Hirano H, Nakagawa H, Fukami T, Oosumi K, Murakami K, et al. A new strategy of high-speed screening and quantitative structure-activity relationship analysis to evaluate human ATP-binding cassette transporter ABCG2-drug interactions. J Pharmacol Exp Ther. 2006;317:1114–24.PubMedCrossRefGoogle Scholar